Is Amplify Weight Loss Drug & Treatment ETF halal to invest in?

As of September 2026, Amplify Weight Loss Drug & Treatment ETF THNR is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.

Is Amplify Weight Loss Drug & Treatment ETF a Shariah-compliant ETF?

An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes Amplify Weight Loss Drug & Treatment ETF using these criteria to determine its compliance status.

How often is the Shariah compliance for Amplify Weight Loss Drug & Treatment ETF updated?

The Shariah compliance status of Amplify Weight Loss Drug & Treatment ETF may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.

Can a halal ETF like Amplify Weight Loss Drug & Treatment ETF become non-compliant?

Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.

Where can I check the Shariah status of Amplify Weight Loss Drug & Treatment ETF?

You can check the latest Shariah compliance status of Amplify Weight Loss Drug & Treatment ETF on Musaffa's ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.

Amplify Weight Loss Drug & Treatment ETF THNR

THNR Shariah Compliance

Screening Methodology: AAOIFI

As of September 2026, Amplify Weight Loss Drug & Treatment ETF is classified as halal.

HALAL

Is Amplify Weight Loss Drug & Treatment ETF Halal?

Shariah Compliance Analysis of THNR ETF

US Equity Health Care

Yes. As of September 2026, Amplify Weight Loss Drug & Treatment ETF (THNR) is classified as HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Amplify Weight Loss Drug & Treatment ETF passes Musaffa's business and financial screening criteria.

THNR was created on 2024-05-21 by Amplify. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 2.85m in AUM and 22 holdings. THNR tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses.

Amplify Weight Loss Drug & Treatment ETF (THNR) Chart

Key Statistics of Amplify Weight Loss Drug & Treatment ETF (THNR)

Today's Open

AUM

Avg. Volume

Expense Ratio

P/E Ratio

P/B Ratio

Sector Exposure

Health Care
69.93%
Other
22.78%
Information Technology
4.60%
Materials
2.69%

FAQ's for Amplify Weight Loss Drug & Treatment ETF (THNR)

As of September 2026, Amplify Weight Loss Drug & Treatment ETF THNR is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
An ETF is considered Shariah-compliant if its underlying assets consist primarily of companies that operate in permissible business activities and meet Islamic financial screening thresholds. Musaffa analyzes Amplify Weight Loss Drug & Treatment ETF using these criteria to determine its compliance status.
The Shariah compliance status of Amplify Weight Loss Drug & Treatment ETF may be updated periodically when new portfolio disclosures, financial statements of underlying companies, or other relevant information becomes available.
Yes. An ETF that is currently Shariah-compliant may become non-compliant if its underlying holdings change or if the financial ratios of the companies within the fund exceed Shariah thresholds.
You can check the latest Shariah compliance status of Amplify Weight Loss Drug & Treatment ETF on Musaffa’s ETF page, where screening results and key indicators are updated to help Muslim investors make informed decisions.